Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

Highlights in myasthenia gravis from AANEM 2024 include efficacy data on efgartigimod, ravulizumab, zilucoplan, and first-in-class inebilizumab, as well as safety outcomes in pregnancy for eculizumab.

Researchers looked for associations of plasma omega-3 and omega-6 polyunsaturated fatty acids with the incidence of cancer.

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...

Increased demands from an aging population and pandemic-related supply shortages leave provinces scrambling to allocate ...

Patients with celiac disease who take an angiotensin receptor blocker (ARB) may experience worse outcomes, such as iron ...

A series of botulism cases in Italy and France have raised concerns about food safety. What can people do to avoid the deadly ...

The US Food and Drug Administration (FDA) sometimes allows cancer drugs with accelerated approvals to remain on the market ...

A disease historically associated with malnourishment on sailing vessels may have a new, modern culprit: Bariatric surgery.

First, there were “Ozempic babies.” Now, there is also Ozempic-before-baby. Unplanned pregnancies are still regularly being ...

Nearly a quarter of patients with hidradenitis suppurativa (HS) experienced concomitant eye disease, and among those who did, ...

Phase 3 study on previously untreated chronic lymphocytic leukemia showed sustained PFS with venetoclax-obinutuzumab.